Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbelaDrug200 in severe head injury
NCT00810940Phase 2Unknown
- Sponsor
- Abela Pharmaceuticals
- Start
- Oct 2010
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AbelaDrug200 in traumatic brain injury (TBI) (2 arms), sponsored by Abela Pharmaceuticals. Primary endpoint: reduction in intracranial pressure at 5 days. Status: unknown.
02
Drugs
AbelaDrug200
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT00810940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00810940.